Rheumatoid Arthritis Treatment Market

Oct 04, 2024

Rheumatoid Arthritis is a chronic, inflammatory autoimmune disease that leads to progressive and destructive polyarthritis and affects approximately 1% of the population. The rheumatoid arthritis population is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joi...

Oct 04, 2024

The past decade experienced a lot of shuffling in the Rheumatoid arthritis market. The journey started with the approvals of disease-modifying anti-rheumatic drugs (DMARDs). Several conventional DMARDs constituting methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine, biologics with initial entrants bei...

Oct 02, 2024

Beyond the shadow of a doubt, the Rheumatoid arthritis treatment market has witnessed strides of improvement during the last few years. There was a time when treatment for rheumatoid arthritis was confined to Non-steroidal anti-inflammatory drugs (NSAIDs) and steroids, which could only address pain and swelling. Ho...